Janssen/Legend Plan Phased US Launch For BCMA-Targeting CAR-T Carvykti
First Multiple Myeloma Patient Could Be Infused In Six Weeks
Janssen priced the one-time autologous treatment at $465,000, well above the $419,500 list price for Bristol’s first-to-market CAR-T, but expects broad commercial and Medicare coverage.
You may also be interested in...
Johnson & Johnson delivered solid third quarter sales and earnings, which led the company to raise 2023 financial guidance.
The company admitted it may not meet a goal set in 2021 to reach a $60bn pharmaceutical revenue target in 2025.
The companies unblinded data from CARTITUDE-4, which met its primary endpoint, but analysts citing KOLs said they continue to face issues with limited manufacturing slots and out-of-spec product.